Sighencea & Trifu 2025 — Viral hypothesis of schizophrenia (cross-condition bridge)

One-paragraph summary

Comprehensive narrative review of the viral hypothesis of schizophrenia. Not FM-direct, but ingested as a bridging paper because the mechanistic framework — multiple neurotropic viruses (influenza, herpesviruses HSV-1/2/CMV/VZV/EBV/HHV-6/8, hepatitis viruses, HIV, HERVs, HTLV, Zika, BoDV, coronaviruses) contributing to disease via direct microinvasion, persistent CNS infection, immune-mediated neuroinflammation, molecular mimicry, and BBB disruption — is structurally identical to the project's emerging viral-genome-modification framework for FM (viral-genome-modification-hypothesis.md). The review supports a "multi-hit" model: viral infections interfere with hereditary and immunological susceptibilities to elevate disease risk. Most directly relevant: the "mild encephalitis hypothesis" — that a subset of schizophrenia cases involves low-grade chronic neuroinflammation that may share substrate with the project's H3 (predictive-coding/network-dysregulation) chain. The review also notes that adjunctive anti-inflammatory therapies show promise, particularly in treatment-resistant cases — analogous to the project's H1 antibody-removal strategies in treatment-resistant FM.

Claims as triples

• viral_infection — bridges → predictive_coding_failure [via mild encephalitis hypothesis; confidence: bridging]
• HERV_reactivation — bridges → neuroinflammation_glial [confirmed across schizophrenia + FM literature; confidence: bridging]
• viral_infection — bridges → autoantibody_mediated_pain [molecular mimicry mechanism; confidence: bridging]

Methods note

Narrative review. No new primary data. Authors: Romanian neuropsychiatry group (Bucharest).

Limitations

• Schizophrenia, not FM. Direct extrapolation requires the viral-pathogenesis mechanism to operate similarly across both conditions, which is plausible but not established.
• Narrative review — selection bias possible.
• "Multi-hit" framing is broadly consistent with FM literature but not specifically validated in FM cohorts.

Open questions raised

• Are the same neurotropic viruses (HSV-1, EBV, HHV-6, HERVs, SARS-CoV-2) implicated in FM with the same prevalence patterns? Cross-condition viral-trigger mapping would test whether FM and schizophrenia share viral substrates.
• Does the "mild encephalitis hypothesis" of schizophrenia translate to a "mild encephalitis hypothesis" of FM? TSPO-PET evidence (Coluzzi 2025 ingested) suggests yes; would justify low-dose anti-inflammatory adjunctive therapy as a candidate FM intervention.
• Does maternal immune activation during pregnancy elevate FM risk in offspring (analogous to the schizophrenia developmental hypothesis)?

Triangulation notes

• Cross-condition validation of the viral-pathogenesis multi-hit model. The same mechanistic framework that's emerging in FM (viral trigger → genome modification or epigenetic reprogramming → chronic immune activation → disease) is well-established in schizophrenia literature — useful as evidence the framework is real, not idiosyncratic.
• Reinforces B6 (post-infectious nociplastic conditions ↔ FM) by extending it to neuropsychiatric conditions. The bridge framework may need to expand: some chronic post-viral conditions (FM, ME/CFS, long COVID, schizophrenia subset) share mechanism but present at different system levels (pain vs psychosis).
• The "treatment-resistant cases respond to anti-inflammatory" pattern in schizophrenia parallels the "treatment-resistant cases respond to antibody-removal" pattern emerging in ME/CFS (Oesch-Régeni 2025, Fluge & Mella 2025). Both suggest immune-axis interventions help the patients who fail standard care.

Bridges

• NEW B8 candidate: Schizophrenia subset ↔ FM via shared viral/immune substrate. Worth tracking but lower priority than B7 (HERV) given FM-direct evidence is stronger.
• B6 reinforced as a multi-condition framework rather than just FM-ME-CFS-long-COVID.